Coronary in-stent restenosis (ISR) is an important complication of percutaneous coronary intervention (PCI). However, the relationship between lipoprotein associated phospholipase A2 (Lp-PLA2) level and ISR after PCI is rarely reported. This study aims to explore the relationship between Lp-PLA2 and the occurrence of ISR at post-PCI and its predictive value for ISR.
Methods and results
Plasma Lp-PLA2 mass were measured in 847 patients planting 1262 stents and evaluated along with known risk indicators. One-year angiographic follow-up showed that baseline elevated Lp-PLA2 mass was strongly associated with early restenosis (95% CI = 1.062-3.050, P < 0.05). Beyond the first year, the occurrence of late restenosis (95% CI = 1.043-3.214, P < 0.05) was significantly larger in the elevated Lp-PLA2 group. Kaplan-Meier analysis after three-year clinical follow up suggested that Lp-PLA2 mass did add the positive effect on the occurrence of major adverse cardiovascular events (MACEs).
Conclusion
In conclusion, increased baseline plasma Lp-PLA2 predicts increased risks of re-stenosis and MACEs, which may be a novel biomarker for predicting ISR and MACEs.
ScottNA.Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev2006;
58: 358–376.
BlumASchneiderDJSobelBE, et al.
Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol2004;
94: 1420–1423.
4.
LiJJFangCHJiangH, et al.
Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal stenosis. Clin Chim Acta2004;
350: 115–121.
5.
LiJJLiJNanJL, et al.
Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects. Med Hypotheses2007;
69: 1004–1009.
6.
IkonomidisIMichalakeasCALekakisJ, et al.
The role of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) in cardiovascular disease. Rev Recent Clin Trials2011;
6: 108–113.
7.
SantosoAKaniawatiMBakriS, et al.
Secretory phospholipase A2 is associated with the odds of acute coronary syndromes through elevation of serum amyloid-A protein. Int J Angiol2013;
22: 49–54.
8.
GargPKNorbyFLPolfusLM, et al.
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: findings from the atherosclerosis risk in communities study (ARIC). Atherosclerosis2018;
268: 12–18.
9.
MaiolinoGBisogniVRossittoG, et al.
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol2015;
7: 609–620.
10.
ZhengDZengFCaiA, et al.
Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis2014;
13: 41.
11.
MoldoveanuEMut-VitcuBTanaseanuGR, et al.
Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem2008;
41: 1429–1433.
12.
ChenQRYouWWuZM, et al.
Relationship between serum lipoprotein-associated phospholipase A2 and intra-stent restenosis after drug-eluting stent implantation in elderly patients with coronary heart disease [Meeting Abstract]. J Am Geriatr Soc2018;
66: S452–S452.
13.
DangasGDClaessenBECaixetaA, et al.
In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol2010;
56: 1897–1907.
14.
KastratiASchomigAEleziS, et al.
Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol1997;
30: 1428–1436.
15.
IvensKGradausFHeeringP, et al.
Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting. Int Urol Nephrol2001;
32: 717–723.
16.
ZhussWuzkHuym.Relationship between plasma lipoprotein associated phospholipase A2 and coronary in-stent restenosis after percutaneous coronary intervention. Tianjin Med J2018;
46: 746–750.
17.
GucfLiujxZhengqk, et al.
Relationship between serum uric acid and coronaryin in-stent restenosis in middle-aged and old patients with coronary heart disease. J Clin Intern Med2017;
34: 242–245.
18.
PalmazJCBaileySMartonD, et al.
Influence of stent design and material composition on procedure outcome. J Vasc Surg2002;
36: 1031–1039.
19.
StefaniniGGHolmesDRJr.Drug-eluting coronary-artery stents. N Engl J Med2013;
368: 254–265.
20.
KimuraTYokoiHNakagawaY, et al.
Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med1996;
334: 561–566.
21.
SchatzRAPalmazJCTioFO, et al.
Balloon-expandable intracoronary stents in the adult dog. Circulation1987;
76: 450–457.
22.
KomatsuRUedaMNarukoT, et al.
Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation1998;
98: 224–233.
23.
ParkDWHongMKMintzGS, et al.
Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late “catch-up” phenomenon from ASPECT study. J Am Coll Cardiol2006;
48: 2432–2439.
24.
NakagawaYKimuraTMorimotoT, et al.
Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher registry). Am J Cardiol2010;
106: 329–336.
25.
AokiJColomboADudekD, et al.
Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation2005;
112: 3876–3883.
26.
KowalskiJKośmiderMPawlickiL, et al.
Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. Int J Cardiol1997;
58: 229–240.
27.
SerranoCVJrRamiresJAVenturinelliM, et al.
Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol1997;
29: 1276–1283.
28.
BoffaMBMarcovinaSMKoschinskyML.Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem2004;
37: 333–343.
29.
TsimikasSTsironisLDTselepisAD.New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol2007;
27: 2094–2099.
30.
GargPKMcClellandRLJennyNS, et al.
Association of lipoprotein-associated phospholipase A(2) and endothelial function in the multi-ethnic study of atherosclerosis (MESA). Vasc Med2011;
16: 247–252.
31.
NakazawaGOtsukaFNakanoM, et al.
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol2011;
57: 1314–1322.
32.
HigoTUedaYOyabuJ, et al.
Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging2009;
2: 616–624.
33.
AsanoKOkamotoSFukunagaK, et al.
Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun1999;
261: 511–514.
34.
StafforiniDMElstadMRMcIntyreTM, et al.
Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem1990;
265: 9682–9687.
35.
LpPThompsonAGaoP, et al.
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet2010;
375: 1536–1544.
36.
PackardCJO’ReillyDSCaslakeMJ, et al.
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med2000;
343: 1148–1155.
37.
SilvaITMelloAPDamascenoNR.Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): a review. Lipids Health Dis2011;
10: 170–101.
